A total of @ patients in the NORDIC VII Study were randomized @ to arm A ( Nordic FLOX ) , arm B ( Nordic FLOX + cetuximab ) , or arm C ( Nordic FLOX + cetuximab for @ weeks followed by cetuximab alone as maintenance therapy ) .